C07D 239/74
With only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring
Official title: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
C07D239/74 (With only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring) appears on 307 US grants and 313 published applications in this corpus.
Search patents in C07D- Granted patents
- 307
- Published applications
- 313
- Assignees
- 204
- Inventors
- 1,206
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 7 | 0 |
| 1989 | 1 | 0 |
| 1990 | 3 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 4 | 0 |
| 1998 | 10 | 0 |
| 1999 | 9 | 0 |
| 2000 | 8 | 0 |
| 2001 | 6 | 4 |
| 2002 | 7 | 2 |
| 2003 | 4 | 5 |
| 2004 | 0 | 7 |
| 2005 | 0 | 18 |
| 2006 | 6 | 9 |
| 2007 | 5 | 15 |
| 2008 | 4 | 9 |
| 2009 | 7 | 13 |
| 2010 | 13 | 16 |
| 2011 | 6 | 8 |
| 2012 | 12 | 9 |
| 2013 | 8 | 10 |
| 2014 | 8 | 11 |
| 2015 | 13 | 15 |
| 2016 | 11 | 16 |
| 2017 | 14 | 22 |
| 2018 | 13 | 20 |
| 2019 | 22 | 13 |
| 2020 | 15 | 16 |
| 2021 | 9 | 12 |
| 2022 | 8 | 13 |
| 2023 | 12 | 20 |
| 2024 | 11 | 13 |
| 2025 | 9 | 10 |
| 2026 | 4 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- TEAD inhibitors and uses thereof16 Jun 2026US 12,655,150 B2Cedilla Therapeutics, Inc.
- GCN2 modulator compounds19 May 2026US 12,630,529 B2Alesta Therapeutics BV
- Quinazoline derivative having FLT3 inhibitory activity, and use thereof5 May 2026US 12,617,758 B2Industry-University Cooperation Foundation Hanyang University Erica Campus
- Compound for organic electrical element, organic electrical element using same and electronic device thereof13 Jan 2026US 12,527,215 B2Duk San Neolux Co., Ltd.
- Compound and composition as PDGF receptor kinase inhibitor30 Dec 2025US 12,509,424 B2Nippon Shinyaku Co., Ltd.
- Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors27 Aug 2026US 2026/0250304 A1Riboscience LLC
- Nitrogen-containing hetreocycles for organic electroluminescent devices27 Aug 2026US 2026/0255779 A1Merck Patent GmbH
- Aryl-containing amine compound, preparation method therefor and use thereof25 Jun 2026US 2026/0174739 A1Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Quinazoline derivative compound and use thereof21 May 2026US 2026/0138959 A1Voronoi Inc.
- Compound and organic light emitting device comprising the same26 Mar 2026US 2026/0090269 A1LG Chem.Ltd.
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties144US 5,721,237 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase110US 5,714,493 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998